Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute and Harvard Medical School, shared a post on X:
“Very promising data with KAT6 inhibition + fulvestrant presented by Pat LoRusso. Among 43 pts with HR+/HER2- MBC, all with prior CDK4/6i, ORR was 37%, mPFS 10.7 months. Main toxicity: 74% with dysgeusia (paging Antonio Giordano for the pronunciation of this tox).”
